| Autor: |
Herrera-Martínez AD; Maimonides Institute for Biomedical Research of Cordoba (IMIBIC), 14004 Córdoba, Spain.; Endocrinology and Nutrition Service, Reina Sofia University Hospital, 14004 Córdoba, Spain., Fuentes-Fayos AC; Maimonides Institute for Biomedical Research of Cordoba (IMIBIC), 14004 Córdoba, Spain.; Department of Cell Biology, Physiology, and Immunology, University of Córdoba, 14004 Córdoba, Spain.; CIBER Physiopathology of Obesity and Nutrition (CIBERobn), 14004 Córdoba, Spain.; Reina Sofia University Hospital, 14004 Cordoba, Spain., Sanchez-Sanchez R; Maimonides Institute for Biomedical Research of Cordoba (IMIBIC), 14004 Córdoba, Spain.; Pathology Service, Reina Sofia University Hospital, 14004 Córdoba, Spain., Montero AJ; Maimonides Institute for Biomedical Research of Cordoba (IMIBIC), 14004 Córdoba, Spain.; Department of Cell Biology, Physiology, and Immunology, University of Córdoba, 14004 Córdoba, Spain.; CIBER Physiopathology of Obesity and Nutrition (CIBERobn), 14004 Córdoba, Spain.; Reina Sofia University Hospital, 14004 Cordoba, Spain., Sarmento-Cabral A; Maimonides Institute for Biomedical Research of Cordoba (IMIBIC), 14004 Córdoba, Spain.; Department of Cell Biology, Physiology, and Immunology, University of Córdoba, 14004 Córdoba, Spain.; CIBER Physiopathology of Obesity and Nutrition (CIBERobn), 14004 Córdoba, Spain.; Reina Sofia University Hospital, 14004 Cordoba, Spain., Gálvez-Moreno MA; Maimonides Institute for Biomedical Research of Cordoba (IMIBIC), 14004 Córdoba, Spain.; Endocrinology and Nutrition Service, Reina Sofia University Hospital, 14004 Córdoba, Spain., Gahete MD; Maimonides Institute for Biomedical Research of Cordoba (IMIBIC), 14004 Córdoba, Spain.; Department of Cell Biology, Physiology, and Immunology, University of Córdoba, 14004 Córdoba, Spain.; CIBER Physiopathology of Obesity and Nutrition (CIBERobn), 14004 Córdoba, Spain.; Reina Sofia University Hospital, 14004 Cordoba, Spain., Luque RM; Maimonides Institute for Biomedical Research of Cordoba (IMIBIC), 14004 Córdoba, Spain.; Department of Cell Biology, Physiology, and Immunology, University of Córdoba, 14004 Córdoba, Spain.; CIBER Physiopathology of Obesity and Nutrition (CIBERobn), 14004 Córdoba, Spain.; Reina Sofia University Hospital, 14004 Cordoba, Spain. |
| Abstrakt: |
Carcinoid heart disease (CHD) is a frequent and life-threatening complication in patients with carcinoid tumors. Its clinical management is challenging is some cases since serotonin-induced valve fibrosis leads to heart failure. Telotristat is an inhibitor of tryptophan-hydroxylase (TPH), a key enzyme in serotonin production. Telotristat use in patients with carcinoid syndrome and uncontrollable diarrhea under somatostatin analogs is approved, but its specific role in patients with CHD is still not clear. IN this context, we aimed to explore the effect of telotristat in heart fibrosis using a mouse model of serotonin-secreting metastasized neuroendocrine neoplasm (NEN). To this aim, four treatment groups (n = 10/group) were evaluated: control, monthly octreotide, telotristat alone, and telotristat combined with octreotide. Plasma serotonin and NT-proBNP levels were determined. Heart fibrosis was histologically evaluated after 6 weeks of treatment or when an individual mouse's condition was close to being terminal. Heart fibrosis was observed in all groups. Non-significant reductions in primary tumor growth were observed in all of the treated groups. Feces volume was increased in all groups. A non-significant decrease in feces volume was observed in the octreotide or telotristat-treated groups, while it was significantly reduced with the combined treatment at the end of the study compared with octreotide (52 g reduction; p < 0.01) and the control (44.5 g reduction; p = 0.05). Additionally, plasma NT-proBNP decreased in a non-significant, but clinically relevant, manner in the octreotide (28.2% reduction), telotristat (45.9% reduction), and the octreotide + telotristat (54.1% reduction) treatment groups. No significant changes were observed in plasma serotonin levels. A similar non-significant decrease in heart valve fibrosis was observed in the three treated groups. In conclusion, Telotristat alone and especially in combination with octreotide decreases NT-proBNP levels in a mouse model of serotonin-secreting metastasized NEN, when compared with the control and octreotide, but its effect on heart valve fibrosis (alone and in combination) was not superior to octreotide in monotherapy. |
